Results 161 to 170 of about 75,808 (286)

Physiology, pathology and therapeutic potential of microglial triggering receptor expressed on myeloid cells 2 signalling: A narrative update

Clinical and Translational Discovery, Volume 6, Issue 3, June 2026.
TREM2hi microglia and macrophages exert distinct roles in neurological diseases. Enhancing TREM2 signalling supports pathological protein or debris clearance and mitigates inflammation in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, demyelination disorders and stroke, whereas blocking TREM2 may alleviate tauopathy and ...
Zhe Kong, Libin Shen, Daqing Ma, Jinchao Hou   +3 more
wiley   +1 more source

RXR Gamma Enables Oligodendrocyte Differentiation by Suppressing Sonic Hedgehog Signaling

Glia, Volume 74, Issue 6, June 2026.
Using pharmacogenetic approaches, Baldassarro et al. demonstrate that RXRγ suppresses the SHH signaling pathway in OPCs to ensure their efficient differentiation following T3 stimulation. Accordingly, Rxrg−/− OPCs displayed compromised differentiation which was normalized by the pharmacological inhibition of the hyperactive SHH pathway.
Vito Antonio Baldassarro, Quentin Brassart, Valérie Fraulob, Laura Calzà, Wojciech Krezel   +4 more
wiley   +1 more source

A Five-Year Retrospective Study: Relationship Between Cervical Spine Whiplash Injuries and Demyelinating Diseases in the Pediatric Population. [PDF]

Cureus
Kardouh MS, Van Wagoner C, Coleman J, Saleh E.   +3 more
europepmc   +1 more source

Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases. [PDF]

Vaccine X, 2023
Zhao D, Zhang W, Ma X, Zhao R, Yao L, Lu J, Yan X, Bai M, Zhang G, Li H, Guo J.   +10 more
europepmc   +1 more source

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab, Barnabas Obeng‐Gyasi, Paul Haste, Matthew Krosin   +3 more
wiley   +1 more source

Spinal fluid antibody profile against bacteria demonstrates intrathecal antibody production in demyelinating diseases. [PDF]

J Mol Med (Berl)
Polidoro EE, Stosiek N, Laman JD, Palmer CA, Kriesel JD.   +4 more
europepmc   +1 more source

Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum. [PDF]

Genes (Basel), 2023
Ortiz GG, Torres-Mendoza BMG, Ramírez-Jirano J, Marquez-Pedroza J, Hernández-Cruz JJ, Mireles-Ramirez MA, Torres-Sánchez ED.   +6 more
europepmc   +1 more source

Pediatric Therapeutic Plasma Exchange: Characterization of Practice, Epidemiology, and Safety Profile at a Children's Hospital in the United States

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT There is a need to better understand the indications and safety profiles for therapeutic plasma exchange (TPE) in children. We aimed to assess pediatric TPE practice at a large academic center by retrospective chart review from 2011 to 2022. Patient demographics and clinical information including American Society for Apheresis (ASFA) category ...
Benjamin C. Lee, Brian D. Adkins, Ayda Javanbakht, Hung S. Luu, Daniel K. Noland   +4 more
wiley   +1 more source

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk. [PDF]

J Crohns Colitis
Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L.   +6 more
europepmc   +1 more source

Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. [PDF]

Front Immunol, 2022
Jiao L, Guo S.
europepmc   +1 more source